Clinical significance of MDM2 as a tumor biomarker

Chinese-German Journal of Clinical Oncology

Volumn 11, Issue 6, 2012, Pages 356-360

  Chen, Hong ^a   Xie, Li ^b   Liu, Baorui ^b  

^a People's Hospital of Yixing City   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

MDM2; Oncogene; P53; Predictive biomarker

Indexed keywords

ALKYLATING AGENT; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; PLATINUM; PROTEIN MDM2; TUMOR MARKER;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SUSCEPTIBILITY; CELL CYCLE REGULATION; CELL PROLIFERATION; CHEMOSENSITIVITY; DISEASE MARKER; ESOPHAGUS CANCER; GENOTYPE; HUMAN; LIVER CANCER; LUNG CANCER; METASTASIS; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER;

EID: 84864646491     PISSN: 16101979     EISSN: 16139089     Source Type: Journal    
DOI: 10.1007/s10330-012-0986-9     Document Type: Article

References (33)

1. Piette J, Neel H, Maréchal V. MDM2: keeping p53 under control. Oncogene, 1997, 15: 1001-1010.
2. Daujat S, Neel H, Piette J. MDM2: Life without p53. Trends Genet, 2001, 17: 459-464.
3. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 2004, 119: 591-602.
4. Hu Z, Jin G, Wang L, et al. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev, 2007, 16: 2717-2723.
5. Gui XH, Qiu LX, Zhang HF, et al. MDM2 309 T/G polymorphism is associated with lung cancer risk among Asians. Eur J Cancer, 2009, 45: 2023-2026.
6. Ohmiya N, Taguchi A, Mabuchi N, et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol, 2006, 24: 4434-4440.
7. Hong Y, Miao X, Zhang X, et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res, 2005, 65: 9582-9587.
8. Xiao M, Zhang L, Zhu X, et al. Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population. BMC Cancer, 2010, 10: 147.
9. Akkiz H, Sümbül AT, Bayram S, et al. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population. Cancer Epidemiol, 2010, 34: 448-452.
10. Onat OE, Tez M, Ozcelik T, et al. MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res, 2006, 26: 3473-3475.
11. Wilkening S, Bermejo JL, Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis, 2007, 28: 2262-2267.
12. Economopoulos KP, Sergentanis TN. Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a metaanalysis. Breast Cancer Res Treat, 2010, 120: 211-216.
13. Geoffrey Liu, Paul Wheatley P, Zhou W, et al. Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk. Int J Cancer, 2008, 122: 915-918.
14. Shi SZ, Zhao JJ, Zhao WH, et al. The expression and clinical significance of FHIT protein and mdm2 protein in non-small cell lung cancer. Chin Clin Oncol (Chinese), 2009, 14: 212-216.
15. Heist RS, Zhou W, Chirieac LR, et al. MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. J Clin Oncol, 2007, 25: 2243-2247.
16. Han JY, Lee GK, Jang DH, et al. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer, 2008, 113: 799-807.
17. Chien WP, Wong RH, Cheng YW, et al. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors. Ann Surg Oncol, 2010, 17: 1194-1202.
18. Karray-Chouayekh S, Baccouche S, Khabir A, et al. Prognostic significance of p16INK4a/p53 in Tunisian patients with breast carcinoma. Acta Histochem, 2011, 113: 508-513.
19. Paulin FE, O'Neill M, McGregor G, et al. MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron1 polymorphism. BMC Cancer, 2008, 8: 281.
20. Turbin DA, Cheang MC, Bajdik CD, et al. MDM2 protein expression is a negative prognostic marker in breast carcinoma. Mod Pathol, 2006, 19: 69-74.
21. Wang XM, Tao FH, Cheng ZQ, et al. Immunohistochemical detection of MDM2 protein in colorectal cancer :Relevance to tumor pathological feature. J Fourth Mil Med Univ (Chinese), 2003, 24: 1356-1358.
22. Yu Y, Chen GH, Hu J, et al. The expression and the biological significance of mdm2 in human colorectal adenocarcinoma. Chin J Clin Oncol (Chinese), 2006, 33: 264-266.
23. Shimada Y, Maeda M, Watanabe G, et al. Cell culture in esophageal squamous cell carcinoma and the association with molecular markers. Clin Cancer Res, 2003, 9: 243-249.
24. Yang QC, Zheng MR, Che XX. Expression of mdm2 in primary hepatocellular carcinoma. Chin J Histochem Cytochem (Chinese), 2004, 13: 503-506.
25. Wang HX, Pan YL, Tan L, et al. Prognostic value of P53 and MDM2 protein expression in hepatocellular carcinoma. J Jinan Uni (Medicine Edition) (Chinese), 2004, 25: 461-467.
26. Liu W, He L, Ramírez J, et al. Interactions between MDM2 and TP53 genetic alterations, and their impact on response to MDM2 inhibitors and other chemotherapeutic drugs in cancer cells. Clin Cancer Res, 2009, 15: 7602-7607.
27. Nayak MS, Yang JM, Hait WN. Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs. Cancer Res, 2007, 67: 5831-5839.
28. Kondo S, Kondo Y, Hara H, et al. MDM2 gene mediates the expression of mdr1 gene and P-glycoprotein in a human glioblastoma cell line. Br J Cancer, 1996, 74: 1263-1268.
29. Zhou M, Gu L, Abshire TC, et al. Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. Leukemia, 2000, 14: 61-67.
30. Tu HF, Chen HW, Kao SY, et al. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation. Radiother Oncol, 2008, 87: 243-252.
31. Shinohara A, Sakano S, Hinoda Y, et al. Hideyasu Matsuyama. Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy. Cancer Sci, 2009, 100: 2376-2382.
32. Cao C, Shinohara ET, Subhawong TK, et al. Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute2. Mol Cancer Ther, 2006, 5: 411-417.
33. Shangary S, Wang S. Small-molecule inhibitors of the MDM2 -p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol, 2009, 49: 223-241.